New gout drug shows promise in major trial
Disease control
Ongoing
This study tests a new medicine called AR882 in 750 adults with gout. The goal is to see if it can lower uric acid levels and reduce painful flare-ups over 12 months. Participants receive either AR882 or a placebo. This is a phase 3 trial, meaning it is one of the final steps bef…
Phase: PHASE3 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated May 06, 2026 16:02 UTC